Dana-Farber Cancer Institute logo

Publications

2023

Nature. 2023 Oct 18. doi: 10.1038/s41586-023-06623-2.
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.
 
Histopathology. 2023 Oct;83(4):569-581. doi: 10.1111/his.15005.
TSC2 inactivation, low mutation burden and high macrophage infiltration characterise hepatic angiomyolipomas.
 
Sci Adv. 2023 Sep 29;9(39):eadd9668. doi: 10.1126/sciadv.add9668.
Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors.
 
Cell Rep Med. 2023 Sep 19;4(9):101189. doi: 10.1016/j.xcrm.2023.101189.
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.
 
Sci Immunol. 2023 Sep 8;8(87):eadf4968. doi: 10.1126/sciimmunol.adf4968.
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
 
Blood Adv. 2023 Aug 22;7(16):4633-4646. doi: 10.1182/bloodadvances.2023009813.
Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging.
 
Cancer Res. 2023 Aug 15;83(16):2645-2655. doi: 10.1158/0008-5472.CAN-22-3114.
Targeting KDM2A Enhances T-cell Infiltration in NSD1-Deficient Head and Neck Squamous Cell Carcinoma.
 
Nat Commun. 2023 Jul 15;14(1):4238. doi: 10.1038/s41467-023-39874-8.
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC.
 
Clin Cancer Res. 2023 Jul 5;29(13):2540-2550. doi: 10.1158/1078-0432.CCR-22-3413.
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
 
Nat Cancer. 2023 Jul;4(7):1036-1052. doi: 10.1038/s43018-023-00576-1.
High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers.
 
bioRxiv [Preprint]. 2023 Jun 29:2023.06.28.546977. doi: 10.1101/2023.06.28.546977.
A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinoma.
 
J Immunother. 2023 Jun 1;46(5):192-196. doi: 10.1097/CJI.0000000000000470.
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy.
 
J Thorac Oncol. 2023 May 27:S1556-0864(23)00578-6. doi: 10.1016/j.jtho.2023.05.019.
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
 
Blood. 2023 Apr 13;141(15):1817-1830. doi: 10.1182/blood.2022018246.
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
 
Blood. 2023 Apr 13;141(15):1884-1888. doi: 10.1182/blood.2022017686.
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
 
bioRxiv [Preprint]. 2023 Mar 23:2023.03.21.533680. doi: 10.1101/2023.03.21.533680.
Inference of single cell profiles from histology stains with the Single-Cell omics from Histology Analysis Framework (SCHAF).
 
Ann Oncol. 2023 Mar;34(3):275-288. doi: 10.1016/j.annonc.2022.12.002.
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
 
Blood Cancer J. 2023 Feb 2;13(1):22. doi: 10.1038/s41408-023-00788-9.
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors.

2022

NPJ Breast Cancer. 2022 Dec 30;8(1):134. doi: 10.1038/s41523-022-00500-3.
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.
 
Cancer Immunol Res. 2022 Dec 2;10(12):1559-1569. doi: 10.1158/2326-6066.CIR-22-0227.
Hippo Signaling Pathway Regulates Cancer Cell-Intrinsic MHC-II Expression.
 
Ann Oncol. 2022 Oct;33(10):1029-1040. doi: 10.1016/j.annonc.2022.07.005.
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer.
 
iScience. 2022 Oct 22;25(11):105426. doi: 10.1016/j.isci.2022.105426.
NF-κB-regulated VentX expression mediates tumoricidal effects of chemotherapeutics at noncytotoxic concentrations.
 
JAMA Oncol. 2022 Aug 1;8(8):1160-1168. doi: 10.1001/jamaoncol.2022.1981.
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
 
JCO Precis Oncol. 2022 Jul;6:e2100413. doi: 10.1200/PO.21.00413.
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.
 
J Clin Invest. 2022 Jul 1;132(13):e151666. doi: 10.1172/JCI151666.
Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma.
 
J Clin Invest. 2022 Jun 1;132(11):e154334. doi: 10.1172/JCI154334.
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.
 
Nature. 2022 May;605(7910):532-538. doi: 10.1038/s41586-022-04682-5.
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.
 
Nat Methods. 2022 Mar;19(3):262-267. doi: 10.1038/s41592-022-01415-4.
MITI minimum information guidelines for highly multiplexed tissue images.
 
J Immunother Cancer. 2022 Mar;10(3):e003569. doi: 10.1136/jitc-2021-003569.
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
 
Lancet Oncol. 2022 Jan 13:S1470-2045(21)00658-6. doi: 10.1016/S1470-2045(21)00658-6.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

2021

J Immunother Cancer. 2021 Nov;9(11):e003536. doi: 10.1136/jitc-2021-003536.
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
 
J Immunother Cancer. 2021 Nov;9(11):e003318. doi: 10.1136/jitc-2021-003318.
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
 
Cancer Research Communications 2021 Oct. 1 (1): 30–40.
Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia
 
Clin Cancer Res. 2021 Sep 15;27(18):5072-5083. doi: 10.1158/1078-0432.
Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network.
 
Blood. 2021 Sep 23;138(12):1081-1085. doi: 10.1182/blood.2021010930.
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
 
Cancer Discov. 2021 Aug;11(8):1952-1969. doi: 10.1158/2159-8290.CD-20-0913.
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. 
 
J Thorac Oncol. 2021 Jul;16(7):1176-1187. doi: 10.1016/j.jtho.2021.03.024.
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
 
NPJ Precis Oncol. 2021 Jun 29;5(1):62. doi: 10.1038/s41698-021-00197-w.
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients.
 
Blood. 2021 Jun 10;137(23):3212-3217. doi: 10.1182/blood.2021010867.
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
 
Cancer Discov. 2021 Jun;11(6):1524-1541. doi: 10.1158/2159-8290.CD-20-0812.
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. 
 
Nat Med. 2021 Mar;27(3):515-525. doi: 10.1038/s41591-020-01206-4. Epub 2021 Jan 21.
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
 
Science. 2021 Jan 29;371(6528): eaax2656. doi: 10.1126/science.aax2656.
Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems.
 
Nat Cancer. 2021 Jan;2(1):66-82. doi: 10.1038/s43018-020-00148-7.
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
 

2020

Blood 2020 Sep 1; doi: 10.1182/blood.2020006464.
Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma
 
JAMA Oncol.2020 Aug 27;6(10):1-9.doi: 10.1001/jamaoncol.2020.2955. Online ahead of print.
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial
 
Blood 2020 Aug 31; doi: 10.1182/blood.2019004753.
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
 
IEEE Trans Med Imaging. 2020 Sep 3;doi: 10.1109/TMI.2020.3021387.
Pathomic Fusion: An Integrated Framework for Fusing Histopathology and Genomic Features for Cancer Diagnosis and Prognosis
 
Nature Med. 2020 Aug 10. doi: 10.1038/s41591-020-1006-1.
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.
 
Ann Oncol. 2020 Aug;31(8):1011-1020. doi: 10.1016/j.annonc.2020.04.011.
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas.
 
Cancer Discov. 2020 Sep;10(9):1296-1311; doi: 10.1158/2159-8290.CD-19-1416. Epub 2020 May 5.
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

Eur J Dermatol. 2020 Aug 1;30(4):352-357. doi: 10.1684/ejd.2020.3846.

Nodular primary cutaneous melanoma is associated with PD-L1 expression
 
J Clin Oncol. 2020 Jul 15:JCO1902103. doi: 10.1200/JCO.19.02103.
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
 
Clin Cancer Res. 2020 Jul 14. doi: 10.1158/1078-0432.CCR-20-1695.
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
 
Blood.2020 Jul 4. pii: blood.2019000215.
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation.
https://www.ncbi.nlm.nih.gov/pubmed/30952672
 
Mod Pathol. 2020 Jul;33(7):1380-1388. doi: 10.1038/s41379-020-0498-z. Epub 2020 Feb 12
Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment.
 
JCI Insight. 2020 Jun 18;5(12):e134612. doi: 10.1172/jci.insight.134612.
Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.
 
JCO Precis Oncol. 2020;4:152-160. doi: 10.1200/PO.19.00294. 
P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response
 
J Immunother Cancer. 2020 May;8(1):e000155. doi: 10.1136/jitc-2019-000155.
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
 
Cell. 2020 Apr 16;181(2):236-249. doi: 10.1016/j.cell.2020.03.053
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
 
Nat Commun. 2020 Mar 19;11(1):1459. doi: 10.1038/s41467-020-15315-8.
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
 
Blood Adv. 2020 Jan 14;4(1):122-126. doi: 10.1182/bloodadvances.2019000784.
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.
 

2019

Blood. 2019 Dec 26;134(26):2369-2382. doi: 10.1182/blood.2019002067.
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.
 
Blood Adv. 2019 Dec 10;3(23):4065-4080. doi: 10.1182/bloodadvances.2019001012.
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.
 
Blood. 2019 Dec 5;134(23):2059-2069. doi: 10.1182/blood.2019002206.
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
 
Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
 
Cancer Immunol Res. 2019 Aug;7(8):1230-1236. doi: 10.1158/2326-6066.CIR-18-0683. 
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer.
 
Clin Cancer Res. 2019 Aug 1;25(15):4644-4655. doi: 10.1158/1078-0432.CCR-19-0173. E
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
 
Oncologist. 2019 Aug;24(8):1013-1021.
Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer.
 
Cancer Cell. 2019 Jun 10;35(6):885-900.e10. doi: 10.1016/j.ccell.2019.05.004.
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
 
Clin Cancer Res. 2019 May 6. pii: clincanres
The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy.
https://www.ncbi.nlm.nih.gov/pubmed/31061067
 
Blood. 2019 Apr 5. pii: blood.2019000215.
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation.
https://www.ncbi.nlm.nih.gov/pubmed/30952672 
 
Nat Immunol. 2019 Mar;20(3):326-336.
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
https://www.ncbi.nlm.nih.gov/pubmed/30778252
 
J Clin Oncol. 2019 Feb 20;37(6):481-489.
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
https://www.ncbi.nlm.nih.gov/pubmed/30620669
 
Nature. 2019 Jan;565(7738):234-239
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
https://www.ncbi.nlm.nih.gov/pubmed/30568305

2018

Pancreas. 2018 Oct;47(9):1123-1129.
Characterization of the Neuroendocrine Tumor Immune Microenvironment.
https://www.ncbi.nlm.nih.gov/pubmed/30153220

Nat Genet. 2018 Sep;50(9):1271-1281.
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
https://www.ncbi.nlm.nih.gov/pubmed/30150660

Nat Med. 2018 Aug;24(8):1143-1150.
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.
https://www.ncbi.nlm.nih.gov/pubmed/30038220

Sci Transl Med. 2018 Jul 18;10(450).
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
https://www.ncbi.nlm.nih.gov/pubmed/30021886

Int J Radiat Oncol Biol Phys. 2018 Jun 27. pii: S0360-3016(18)30795-8.
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
https://www.ncbi.nlm.nih.gov/pubmed/29960819

Oncoimmunology. 2018 Mar 19;7(7):e1442999.
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.
https://www.ncbi.nlm.nih.gov/pubmed/29900052

Oncoimmunology. 2018 Mar 13;7(7):e1440930.
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.
https://www.ncbi.nlm.nih.gov/pubmed/29900046

Blood. 2018 Jun 7. pii: blood-2018-04-843714.
Mass cytometry of Hodgkin lymphoma reveals a CD4+ exhausted T-effector and T-regulatory cell rich microenvironment.
https://www.ncbi.nlm.nih.gov/pubmed/29880615

Sci Adv. 2018 Mar 7;4(3):eaar2766. doi:
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
http://www.ncbi.nlm.nih.gov/pubmed/29532035

J Clin Oncol. 2018 Feb 2:JCO2017773994.
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
http://www.ncbi.nlm.nih.gov/pubmed/29394125

Mod Pathol. 2018 Feb;31(2):214-234.
Implications of the tumor immune microenvironment for staging and therapeutics.
http://www.ncbi.nlm.nih.gov/pubmed/29192647

 

2017

Blood Adv. 2017 Dec 12;1(26):2643-2654.
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.Biol Blood Marrow Transplant.
http://www.ncbi.nlm.nih.gov/pubmed/29296917

Cancer Immunol Res. 2017 Nov;5(11):1046-1055.
Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.
http://www.ncbi.nlm.nih.gov/pubmed/29038297

Blood. 2017 Nov 30;130(22):2420-2430.
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
http://www.ncbi.nlm.nih.gov/pubmed/28893733

Br J Cancer. 2017 Oct 24;117(9):1258-1268.
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.An immunogenic personal neoantigen vaccine for patients with melanoma.
http://www.ncbi.nlm.nih.gov/pubmed/28678778

Nature. 2017 Jul 13;547(7662):217-221.
An immunogenic personal neoantigen vaccine for patients with melanoma.
http://www.ncbi.nlm.nih.gov/pubmed/28678778

J Immunother Cancer. 2017 Jul 18;5(1):61.
Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.
http://www.ncbi.nlm.nih.gov/pubmed/28716097

Cancer Immunol Res. 2017 Jun;5(6):446-454.
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
https://www.ncbi.nlm.nih.gov/pubmed/28473314

Cancer Immunol Res. 2017 Jun;5(6):480-492.
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
https://www.ncbi.nlm.nih.gov/pubmed/28522460

J Clin Oncol. 2017 Jun 1;35(16):1836-1844.
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
https://www.ncbi.nlm.nih.gov/pubmed/28406723

Cancer. 2017 Apr 25.
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
https://www.ncbi.nlm.nih.gov/pubmed/28440953

Blood. 2017 Mar 29. pii: blood-2017-01-764209.
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
https://www.ncbi.nlm.nih.gov/pubmed/28356247

Immunity. 2017 Feb 21;46(2):197-204.
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
https://www.ncbi.nlm.nih.gov/pubmed/28228279

Oncoimmunology. 2017 Jan 6;6(2)
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
https://www.ncbi.nlm.nih.gov/pubmed/28344892

Cancer Immunol Res. 2017 Jan;5(1):17-28.
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
https://www.ncbi.nlm.nih.gov/pubmed/28003187

2016

Cancer Immunol Res. 2016 Dec;4(12):1038-1048.
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
https://www.ncbi.nlm.nih.gov/pubmed/27856426

Cancer Immunol Res. 2016 Nov;4(11):910-916.
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
https://www.ncbi.nlm.nih.gov/pubmed/27737878

Cancer Med. 2016 Nov;5(11):3041-3050.
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
https://www.ncbi.nlm.nih.gov/pubmed/27748045

Genome Biol. 2016 Aug 22;17(1):174
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
https://www.ncbi.nlm.nih.gov/pubmed/27549193

Lancet Oncol. 2016 Sep;17(9):1283-94.
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
https://www.ncbi.nlm.nih.gov/pubmed/27451390

Cancer Immunol Res. 2016 Feb;4(2):124-35.
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
https://www.ncbi.nlm.nih.gov/pubmed/26546453

Lab Invest. 2017 Feb;97(2):207-216.
Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.
https://www.ncbi.nlm.nih.gov/pubmed/27918555

Cancer Immunol Res. 2016 Aug 22
VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma
https://www.ncbi.nlm.nih.gov/pubmed/27549123

N Engl J Med. 2016 Jul 14;375(2):143-53
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
https://www.ncbi.nlm.nih.gov/pubmed/27410923

Cancer Immunol Res. 2016 Aug;4(8):679-87.
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.
https://www.ncbi.nlm.nih.gov/pubmed/27312343

Gut. 2016 May 5
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
https://www.ncbi.nlm.nih.gov/pubmed/27196573

J Clin Oncol. 2016 Aug 10;34(23):2698-704
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
https://www.ncbi.nlm.nih.gov/pubmed/27269947

Oncotarget. 2016 May 31;7(22):32925-32
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
https://www.ncbi.nlm.nih.gov/pubmed/27147580

J Clin Oncol. 2016 Aug 10;34(23):2690-7
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
https://www.ncbi.nlm.nih.gov/pubmed/27069084

JAMA Oncol. 2016 Apr;2(4):518-22.
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
https://www.ncbi.nlm.nih.gov/pubmed/26913631

Nat Commun. 2016 Feb 17;7:10501
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
https://www.ncbi.nlm.nih.gov/pubmed/26883990

Oncotarget. 2016 Mar 22;7(12):13587-98.
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
https://www.ncbi.nlm.nih.gov/pubmed/26871470

Am J Surg Pathol. 2016 Apr;40(4):443-53.
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
https://www.ncbi.nlm.nih.gov/pubmed/26752545

Blood. 2016 Feb 18;127(7):869-81.
Targetable genetic features of primary testicular and primary central nervous system lymphomas.
https://www.ncbi.nlm.nih.gov/pubmed/26702065

2015

JAMA Oncol. 2015 Dec;1(9):1319-23.
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
https://www.ncbi.nlm.nih.gov/pubmed/26181000

Cancer Immunol Res. 2015 Dec;3(12):1308-15
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
https://www.ncbi.nlm.nih.gov/pubmed/26546452

J Thorac Oncol. 2015 Dec;10(12):1726-35.
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
https://www.ncbi.nlm.nih.gov/pubmed/26473645

Cancer Immunol Res. 2015 Oct;3(10):1123-9.
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
https://www.ncbi.nlm.nih.gov/pubmed/26081225

Semin Diagn Pathol. 2015 Sep;32(5):381-91.
Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations.
https://www.ncbi.nlm.nih.gov/pubmed/25769206

Oncotarget. 2015 Mar 10;6(7):4704-16.
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
https://www.ncbi.nlm.nih.gov/pubmed/25609200

Cancer Immunol Res. 2015 Aug;3(8):855-63.
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
https://www.ncbi.nlm.nih.gov/pubmed/26014096

N Engl J Med. 2015 Jan 22;372(4):311-9.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
https://www.ncbi.nlm.nih.gov/pubmed/25482239

2013/2014

Cancer Discov. 2013 Dec;3(12):1355-63.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
https://www.ncbi.nlm.nih.gov/pubmed/24078774

Clin Cancer Res. 2013 Jul 1;19(13):3462-73.
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
https://www.ncbi.nlm.nih.gov/pubmed/23674495

Clin Cancer Res. 2014 May 15;20(10):2674-83.
Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
https://www.ncbi.nlm.nih.gov/pubmed/24610827

Cancer Immunol Res. 2014 Jul;2(7):632-42.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306338

Am J Surg Pathol. 2014 Dec;38(12):1715-23
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.
https://www.ncbi.nlm.nih.gov/pubmed/25025450

2009/2012

Cancer Res. 2012 Apr 1;18(7):2117.
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
https://www.ncbi.nlm.nih.gov/pubmed/22271878

J Immunol. 2011 Jan 1;186(1):121-31
Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.
https://www.ncbi.nlm.nih.gov/pubmed/21131428

Genes Chromosomes Cancer. 2011 May;50(5):
Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma.
https://www.ncbi.nlm.nih.gov/pubmed/21305641

J Immunol. 2009 Jul 15;183(2):993-1004.
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes.
https://www.ncbi.nlm.nih.gov/pubmed/19561093